Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

2.

Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.

Yang H, Laurenza A, Williams B, Patten A, Hussein Z, Ferry J.

Epilepsy Res. 2015 Aug;114:122-30. doi: 10.1016/j.eplepsyres.2015.04.010. Epub 2015 May 1.

3.

A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.

Tatosian DA, Cardillo Marricco N, Glasgow XS, DeGroot B, Dunnington K, George L, Gendrano IN, Johnson-Levonas AO, Swearingen D, Kauh E.

Clin Pharmacol Drug Dev. 2016 Sep;5(5):383-92. doi: 10.1002/cpdd.260. Epub 2016 Apr 29.

PMID:
27627194
4.
5.

Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.

Das S, Armstrong J, Mathews D, Li J, Edeki T.

J Clin Pharmacol. 2014 Mar;54(3):331-40. doi: 10.1002/jcph.199. Epub 2013 Oct 22.

PMID:
24150927
6.

Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants.

Suico JG, Friedrich S, Krueger KA, Zhang W.

J Cardiovasc Pharmacol Ther. 2014 May;19(3):283-9. doi: 10.1177/1074248413510784. Epub 2013 Nov 22.

PMID:
24271137
7.

Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.

Hofmann C, Banken L, Hahn M, Swearingen D, Nagel S, Martin-Facklam M.

Clin Ther. 2012 Oct;34(10):2061-71. doi: 10.1016/j.clinthera.2012.08.010. Epub 2012 Sep 12.

PMID:
22980315
8.

A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.

Khalilieh SG, Yee KL, Fan L, Liu R, Heber W, Dunzo E, Triantafyllou I, Hussaini A, Iwamoto M.

Clin Drug Investig. 2017 Oct;37(10):975-984. doi: 10.1007/s40261-017-0552-x.

PMID:
28785879
9.
10.

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.

Darpö B, Sager P, MacConell L, Cirincione B, Mitchell M, Han J, Huang W, Malloy J, Schulteis C, Shen L, Porter L.

Br J Clin Pharmacol. 2013 Apr;75(4):979-89. doi: 10.1111/j.1365-2125.2012.04416.x.

11.

Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects.

Spyker DA, Voloshko P, Heyman ER, Cassella JV.

J Clin Pharmacol. 2014 Jun;54(6):665-74. doi: 10.1002/jcph.257. Epub 2014 Jan 22.

PMID:
24375070
12.

Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.

Zhou D, So K, Dymond AW, Vik T, Al-Huniti N, Mariani G, Zorenyi G, Huang Y, Holmes V, Severin P, Rasmussen S, Martin P.

Clin Ther. 2016 Dec;38(12):2555-2566. doi: 10.1016/j.clinthera.2016.10.004. Epub 2016 Nov 9.

13.

Deferasirox does not induce QT/QTc-prolongation in healthy subjects.

Sechaud R, Dumortier T, Balez S.

Int J Clin Pharmacol Ther. 2009 May;47(5):321-7.

PMID:
19473594
14.

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

Shakeri-Nejad K, Aslanis V, Veldandi UK, Mooney L, Pezous N, Brendani B, Juan A, Allison M, Perry R, Legangneux E.

Clin Ther. 2015 Nov 1;37(11):2489-2505.e2. doi: 10.1016/j.clinthera.2015.09.006. Epub 2015 Oct 27.

PMID:
26519230
15.

QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.

Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, Francis JL, Desaiah D, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Derby M.

J Cardiovasc Pharmacol. 2007 Mar;49(3):146-53.

PMID:
17414226
16.

Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.

de Kam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P.

Int J Clin Pharmacol Ther. 2012 Aug;50(8):595-604. doi: 10.5414/CP201693.

PMID:
22735462
17.

Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.

Wang Z, Xuan F, Lin WH, Troyer MD, Tendolkar A, Cutler DL.

Eur J Clin Pharmacol. 2013 Oct;69(10):1761-7. doi: 10.1007/s00228-013-1541-5. Epub 2013 Jul 16.

PMID:
23857248
18.

Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.

Zhang W, Smulders R, Abeyratne A, Dietz A, Krauwinkel W, Kadokura T, Keirns J.

Clin Ther. 2013 Aug;35(8):1150-1161.e3. doi: 10.1016/j.clinthera.2013.06.009. Epub 2013 Aug 2.

PMID:
23910665
19.

Effects of three fluoroquinolones on QT interval in healthy adults after single doses.

Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R.

Clin Pharmacol Ther. 2003 Apr;73(4):292-303.

PMID:
12709719
20.

A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.

Mansbach RS, Ludington E, Rogowski R, Kittrelle JP, Jochelson P.

Clin Ther. 2011 Jul;33(7):851-62. doi: 10.1016/j.clinthera.2011.05.092. Epub 2011 Jul 1.

PMID:
21722958

Supplemental Content

Support Center